hrqol and pain outcomes in mcrpc: abi ala vs abi pbo in propel
Published 1 year ago • 70 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:15
magnitude: hrqol in patients with mcrpc receiving niraparib and abiraterone
-
1:45
the propel clinical trial exploring olaparib plus abiraterone in mcrpc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
0:51
propel: analysis of drug interactions between olaparib abiraterone as 1l therapy in mcrpc
-
0:44
propel: gene-by-gene efficacy of olaparib and abiraterone in mcrpc
-
3:47
elucidating hrrm status in patients with mcrpc in the propel trial
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
6:41
esmo expert report on combination therapy in advanced prostate cancer @ asco gu 2022
-
1:19
highlights in prostate cancer from esmo
-
1:39
dr. howard scher on corticosteroids during treatment with enzalutamide in mcrpc
-
5:36
propel trial
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
0:49
unmet needs for patients with prostate cancer
-
2:34
ar-v7 as a biomarker in crpc
-
14:14
management of mcrpc in china
-
2:26
charles ryan, md: the efficacy of abiraterone plus prednisone in an elderly patient population
-
1:26
dr. oh discusses choosing abiraterone in prostate cancer
-
1:12
dr. pal on sequencing abiraterone and enzalutamide in mcrpc
-
11:00
treatment approaches for newly diagnosed mcrpc